Paramita Chakrabarty,
Assistant Professor
Department:
MD-NEUROSCIENCE-GENERAL
Business Phone:
(352) 273-7271
Business Email:
pchakrabarty@ufl.edu
About Paramita Chakrabarty
Dr. Paramita Chakrabarty is an Assistant Professor in Neuroscience. She received her PhD from Jawaharlal Nehru University (New Delhi, India) on functional characterization of calcium binding proteins in intestinal parasites. Following this, she shifted gears to train in neuroscience as she became intrigued by how the brain function declines during aging, especially investigating what triggers age-related sporadic neurodegenerative diseases. She completed her postdoctoral training at the University of Washington and the Mayo Clinic (Jacksonville). She rose through the ranks at the University of Florida and established her independent lab where her broad focus is investigating the role of neuroinflammation in neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. Dr. Chakrabarty’s passion, aside from her research, is in mentoring undergraduate and graduate students. She is involved in mentoring pre-doctoral trainees under a T32 training program in Alzheimer’s disease and related dementias and she also participates in shared governance at the College and University level. When she is not at the lab, she likes to take walks, read books and listen to an eclectic mix of music that spans different cultures.
Accomplishments
Excellence Award for Assistant Professors
2021
·
University of Florida
Exemplary Teacher Award
2020
·
University of Florida College of Medicine
McKnight Brain Institute Fellow in Research Leadership Award
2018
·
University of Florida
McKnight Brain Institute Travel Award
2016
·
University of Florida
BJ & Eve Wilder Fellowship in Alzheimer’s disease
2013
·
University of Florida
Robert & Clarice Smith Fellowship
2005
·
Mayo Clinic, Jacksonville
Senior Research Fellow
1998-2002
·
Council of Scientific and Industrial Research, India
Research Profile
Finding effective therapy for Alzheimer’s disease (AD) is a major unmet medical need. Given the genetic association between innate immunity and AD, there is a strong scientific rationale for pursuing research on characterizing therapies targeting immune function as disease modifying therapy in AD and related dementias. We believe that the innate immune system can be potentially harnessed to produce a beneficial disease modifying effect depending on the time and context of immune manipulation. Using various mouse models of AD and related dementias, my laboratory’s work focuses not only on discovering immune pathways linked to these diseases but also testing the efficacy of immune-based therapeutics. The overarching idea for my future research is to harness the effectiveness of these immunobiotherapies, alone or in combination with other existing therapies, for not only Alzheimer’s disease but further extending these ideas to target tauopathies and synucleinopathies.
Open Researcher and Contributor ID (ORCID)
0000-0002-6226-3776
Areas of Interest
- Alzheimer’s Disease
- Amyotrophic Lateral Sclerosis
- Brain imaging
- Disease Modeling
- Gene therapy
- Inflammation
- Parkinson’s disease
- Prion
Publications
2021
Advanced Tau Pathology and Prion-like Propagation in a Monkey Model of Alzheimer’s Disease
Alzheimers Dement.
[DOI] 10.1002/alz.12318.
View on:
Publisher’s Site
2021
Astrocytic apoE4 and tau: Deadly combination for neurons.
Cell reports. Medicine.
2(6)
[DOI] 10.1016/j.xcrm.2021.100316.
[PMID] 34195681.
2021
Author Correction: IL-10 based immunomodulation initiated at birth extends lifespan in a familial mouse model of amyotrophic lateral sclerosis.
Scientific reports.
11(1)
[DOI] 10.1038/s41598-021-83092-5.
[PMID] 33536539.
2021
Combinatorial model of amyloid β and tau reveals synergy between amyloid deposits and tangle formation
Neuropathology and Applied Neurobiology.
[DOI] 10.1111/nan.12779.
[PMID] 34825397.
2021
Il-10 signaling reduces survival in mouse models of synucleinopathy
npj Parkinson's Disease.
7(1)
[DOI] 10.1038/s41531-021-00169-8.
View on:
Publisher’s Site
2021
Integrative functional genomic analysis of intron retention in human and mouse brain with Alzheimer’s disease.
Alzheimer's & dementia : the journal of the Alzheimer's Association.
17(6):984-1004
[DOI] 10.1002/alz.12254.
[PMID] 33480174.
2021
Microglia show differential transcriptomic response to Aβ peptide aggregates ex vivo and in vivo.
Life science alliance.
4(7)
[DOI] 10.26508/lsa.202101108.
[PMID] 34127518.
2021
Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy.
Molecular neurodegeneration.
16(1)
[DOI] 10.1186/s13024-021-00453-4.
[PMID] 33957936.
2020
Differential cross-seeding properties of tau and α-synuclein in mouse models of tauopathy and synucleinopathy
Brain Communications.
2(2)
[DOI] 10.1093/braincomms/fcaa090.
[PMID] 33094280.
2020
Diffusion magnetic resonance imaging-derived free water detects neurodegenerative pattern induced by interferon-γ.
Brain structure & function.
225(1):427-439
[DOI] 10.1007/s00429-019-02017-1.
[PMID] 31894407.
2020
Diversity in Aβ deposit morphology and secondary proteome insolubility across models of Alzheimer-type amyloidosis.
Acta neuropathologica communications.
8(1)
[DOI] 10.1186/s40478-020-00911-y.
[PMID] 32252825.
2020
IL-10 based immunomodulation initiated at birth extends lifespan in a familial mouse model of amyotrophic lateral sclerosis.
Scientific reports.
10(1)
[DOI] 10.1038/s41598-020-77564-3.
[PMID] 33257786.
2020
Intracerebral Expression of AAV-APOE4 Is Not Sufficient to Alter Tau Burden in Two Distinct Models of Tauopathy
Molecular Neurobiology.
57(4):1986-2001
[DOI] 10.1007/s12035-019-01859-4.
[PMID] 31903524.
2020
Meta-Analysis of the Alzheimer’s Disease Human Brain Transcriptome and Functional Dissection in Mouse Models.
Cell reports.
32(2)
[DOI] 10.1016/j.celrep.2020.107908.
[PMID] 32668255.
2020
Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS/FTD mice.
Proceedings of the National Academy of Sciences of the United States of America.
117(31):18591-18599
[DOI] 10.1073/pnas.2005748117.
[PMID] 32690681.
2020
Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer’s disease and other tauopathies.
Acta neuropathologica communications.
8(1)
[DOI] 10.1186/s40478-020-00967-w.
[PMID] 32571418.
2020
Tau-Mediated Dysregulation of Neuroplasticity and Glial Plasticity.
Frontiers in molecular neuroscience.
13
[DOI] 10.3389/fnmol.2020.00151.
[PMID] 32973446.
2020
Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease
Molecular Neurodegeneration.
15(1)
[DOI] 10.1186/s13024-020-0358-9.
[PMID] 32005122.
2020
West Nile Virus-Induced Neurologic Sequelae-Relationship to Neurodegenerative Cascades and Dementias.
Current tropical medicine reports.
7(1):25-36
[DOI] 10.1007/s40475-020-00200-7.
[PMID] 32775145.
2020
α-Synuclein Induces Progressive Changes in Brain Microstructure and Sensory-Evoked Brain Function That Precedes Locomotor Decline.
The Journal of neuroscience : the official journal of the Society for Neuroscience.
40(34):6649-6659
[DOI] 10.1523/JNEUROSCI.0189-20.2020.
[PMID] 32669353.
2019
Alzheimer’s disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph.
Alzheimer's research & therapy.
11(1)
[DOI] 10.1186/s13195-019-0469-0.
[PMID] 30711010.
2019
An anti-CRF antibody suppresses the HPA axis and reverses stress-induced phenotypes
Journal of Experimental Medicine.
216(11):2479-2491
[DOI] 10.1084/jem.20190430.
[PMID] 31467037.
2019
APP-Mediated Signaling Prevents Memory Decline in Alzheimer’s Disease Mouse Model.
Cell reports.
27(5):1345-1355.e6
[DOI] 10.1016/j.celrep.2019.03.087.
[PMID] 31042463.
2019
Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy
Human Molecular Genetics.
28(19):3255-3269
[DOI] 10.1093/hmg/ddz151.
[PMID] 31261380.
2019
Free-water imaging of the hippocampus is a sensitive marker of Alzheimer’s disease.
NeuroImage. Clinical.
24
[DOI] 10.1016/j.nicl.2019.101985.
[PMID] 31470214.
2019
Integrative approach to sporadic Alzheimer’s disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau.
Molecular psychiatry.
24(9):1383-1397
[DOI] 10.1038/s41380-018-0258-3.
[PMID] 30283031.
2019
Neurite orientation dispersion and density imaging reveals white matter and hippocampal microstructure changes produced by Interleukin-6 in the TgCRND8 mouse model of amyloidosis.
NeuroImage.
202
[DOI] 10.1016/j.neuroimage.2019.116138.
[PMID] 31472250.
2019
rAAV-based brain slice culture models of Alzheimer’s and Parkinson’s disease inclusion pathologies
Journal of Experimental Medicine.
216(3):539-555
[DOI] 10.1084/jem.20182184.
[PMID] 30770411.
2019
α-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease
Acta Neuropathologica.
138(1):1-21
[DOI] 10.1007/s00401-019-01977-2.
[PMID] 30798354.
2018
Conserved brain myelination networks are altered in Alzheimer’s and other neurodegenerative diseases.
Alzheimer's & dementia : the journal of the Alzheimer's Association.
14(3):352-366
[DOI] 10.1016/j.jalz.2017.09.012.
[PMID] 29107053.
2018
Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.
The Journal of biological chemistry.
293(12)
[DOI] 10.1074/jbc.AAC118.002657.
[PMID] 29572329.
2018
Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.
The Journal of biological chemistry.
293(7):2408-2421
[DOI] 10.1074/jbc.M117.815357.
[PMID] 29259137.
2018
Ifngr1 and Stat1 mediated canonical Ifn-γ signaling drives nigrostriatal degeneration.
Neurobiology of disease.
110:133-141
[DOI] 10.1016/j.nbd.2017.11.007.
[PMID] 29196213.
2018
Motor neuron loss and neuroinflammation in a model of α-synuclein-induced neurodegeneration
Neurobiology of Disease.
120:98-106
[DOI] 10.1016/j.nbd.2018.09.005.
[PMID] 30195075.
2018
Novel monoclonal antibodies targeting the microtubule-binding domain of human tau.
PloS one.
13(4)
[DOI] 10.1371/journal.pone.0195211.
[PMID] 29608591.
2018
TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer’s disease
Journal of Experimental Medicine.
215(9):2247-2264
[DOI] 10.1084/jem.20180484.
[PMID] 30158114.
2017
A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies.
PloS one.
12(9)
[DOI] 10.1371/journal.pone.0184731.
[PMID] 28910367.
2017
Amyloid β peptides overexpression in retinal pigment epithelial cells via AAV-mediated gene transfer mimics AMD-like pathology in mice.
Scientific reports.
7(1)
[DOI] 10.1038/s41598-017-03397-2.
[PMID] 28607377.
2017
Combination of Aβ Suppression and Innate Immune Activation in the Brain Significantly Attenuates Amyloid Plaque Deposition.
The American journal of pathology.
187(12):2886-2894
[DOI] 10.1016/j.ajpath.2017.08.010.
[PMID] 28919107.
2017
Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau.
Acta neuropathologica communications.
5(1)
[DOI] 10.1186/s40478-017-0458-0.
[PMID] 28760159.
2017
Inflammatory pre-conditioning restricts the seeded induction of α-synuclein pathology in wild type mice.
Molecular neurodegeneration.
12(1)
[DOI] 10.1186/s13024-016-0142-z.
[PMID] 28049533.
2017
Intrastriatal injection of α-synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity.
Molecular neurodegeneration.
12(1)
[DOI] 10.1186/s13024-017-0182-z.
[PMID] 28552073.
2017
Proteolysis of α-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology.
Journal of neurochemistry.
140(4):662-678
[DOI] 10.1111/jnc.13743.
[PMID] 27424880.
2017
Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease.
Nature genetics.
49(9):1373-1384
[DOI] 10.1038/ng.3916.
[PMID] 28714976.
2016
Microglia-specific targeting by novel capsid-modified AAV6 vectors.
Molecular therapy. Methods & clinical development.
3
[DOI] 10.1038/mtm.2016.26.
[PMID] 27308302.
2016
Non-prion-type transmission in A53T α-synuclein transgenic mice: a normal component of spinal homogenates from naïve non-transgenic mice induces robust α-synuclein pathology.
Acta neuropathologica.
131(1):151-4
[DOI] 10.1007/s00401-015-1505-1.
[PMID] 26541429.
2015
Appoptosin-Mediated Caspase Cleavage of Tau Contributes to Progressive Supranuclear Palsy Pathogenesis.
Neuron.
87(5):963-75
[DOI] 10.1016/j.neuron.2015.08.020.
[PMID] 26335643.
2015
IFN-γ promotes τ phosphorylation without affecting mature tangles.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
29(10):4384-98
[DOI] 10.1096/fj.15-275834.
[PMID] 26156074.
2015
IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior.
Neuron.
85(3):519-33
[DOI] 10.1016/j.neuron.2014.11.020.
[PMID] 25619653.
2015
Inefficient induction and spread of seeded tau pathology in P301L mouse model of tauopathy suggests inherent physiological barriers to transmission.
Acta neuropathologica.
130(2):303-5
[DOI] 10.1007/s00401-015-1444-x.
[PMID] 25982997.
2015
Viral expression of ALS-linked ubiquilin-2 mutants causes inclusion pathology and behavioral deficits in mice.
Molecular neurodegeneration.
10
[DOI] 10.1186/s13024-015-0026-7.
[PMID] 26152284.
2015
Widespread and efficient transduction of spinal cord and brain following neonatal AAV injection and potential disease modifying effect in ALS mice.
Molecular therapy : the journal of the American Society of Gene Therapy.
23(1):53-62
[DOI] 10.1038/mt.2014.180.
[PMID] 25228069.
2013
Alzheimer’s disease risk alleles in TREM2 illuminate innate immunity in Alzheimer’s disease.
Alzheimer's research & therapy.
5(3)
[DOI] 10.1186/alzrt178.
[PMID] 23692967.
2013
Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain.
PloS one.
8(6)
[DOI] 10.1371/journal.pone.0067680.
[PMID] 23825679.
2013
Normal cognition in transgenic BRI2-Aβ mice.
Molecular neurodegeneration.
8
[DOI] 10.1186/1750-1326-8-15.
[PMID] 23663320.
2013
Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy.
Acta neuropathologica.
126(1):39-50
[DOI] 10.1007/s00401-013-1123-8.
[PMID] 23666556.
2012
Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition.
Molecular neurodegeneration.
7
[DOI] 10.1186/1750-1326-7-36.
[PMID] 22838967.
2012
Overlapping profiles of Aβ peptides in the Alzheimer’s disease and pathological aging brains.
Alzheimer's research & therapy.
4(3)
[DOI] 10.1186/alzrt121.
[PMID] 22621179.
2012
Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathology.
Molecular neurodegeneration.
7
[DOI] 10.1186/1750-1326-7-39.
[PMID] 22892055.
2011
Hippocampal expression of murine TNFα results in attenuation of amyloid deposition in vivo.
Molecular neurodegeneration.
6
[DOI] 10.1186/1750-1326-6-16.
[PMID] 21324189.
2011
Interferon-γ induces progressive nigrostriatal degeneration and basal ganglia calcification.
Nature neuroscience.
14(6):694-6
[DOI] 10.1038/nn.2829.
[PMID] 21572432.
2010
IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice.
Journal of immunology (Baltimore, Md. : 1950).
184(9):5333-43
[DOI] 10.4049/jimmunol.0903382.
[PMID] 20368278.
2010
Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
24(2):548-59
[DOI] 10.1096/fj.09-141754.
[PMID] 19825975.
2007
Conditional neuronal simian virus 40 T antigen expression induces Alzheimer-like tau and amyloid pathology in mice.
The Journal of neuroscience : the official journal of the Society for Neuroscience.
27(11):2969-78
[PMID] 17360920.
View on:
PubMed
2006
Interleukin-1 receptor 1 knockout has no effect on amyloid deposition in Tg2576 mice and does not alter efficacy following Abeta immunotherapy.
Journal of neuroinflammation.
3
[PMID] 16872492.
View on:
PubMed
2004
Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice.
The American journal of pathology.
165(3):843-53
[PMID] 15331409.
View on:
PubMed
2004
Identification and Characterization of EhCaBP2: a second member of the Calcium-Binding Protein family of the Protozoan Parasite Entamoeba histolytica
Journal of Biological Chemistry.
2000
Calcium binding protein of Entamoeba histolytica
Archives of Medical Research.
31(4):S57-59
Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways
.
[DOI] 10.1101/2021.11.08.467701.
View on:
Publisher’s Site
Grants
May 2021
ACTIVE
Mechanisms and therapeutic potential of vagus nerve stimulation in aging and Alzheimers disease
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Sep 2020
ACTIVE
A Systems Approach to Targeting Innate Immunity in AD
Role: Co-Investigator
Funding: MAYO CLINIC
via NATL INST OF HLTH NIA
Sep 2020
ACTIVE
Validate PFF a-syn induced inflammatory phenotype in mice.
Role: Co-Investigator
Funding: FOX FOU, MICHAEL J
Aug 2020
ACTIVE
Age-associated impaired executive function: Rescue by NMDA receptor upregulation
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Jun 2020
– Apr 2021
Developing a tau based NHP model of AD
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA DAVIS
via MILLENNIUM PHARMACEUTICAL
Mar 2019
– Feb 2021
Mechanisms of abnormal neuronal tau accumulation, interactions with amyloid-beta and pathological sequelae
Role: Co-Investigator
Funding: FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER
Feb 2019
ACTIVE
Metabolic Interventions for Enhancing Cognitive Resilience in Aging and Alzheimers Disease.
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Sep 2018
– Aug 2020
A Systems Approach to Targeting Innate Immunity in AD
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Sep 2018
ACTIVE
Prion and non-prion induction mechanisms of alpha-synuclein pathology
Role: Co-Investigator
Funding: NATL INST OF HLTH NINDS
Sep 2018
ACTIVE
Decision making and basolateral amygdala dysfunction in aging
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Sep 2018
– Apr 2019
A tau-based monkey model of Alzheimers Disease
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA DAVIS
via NATL INST OF HLTH OD
Jun 2018
ACTIVE
APOE as a modifier of prion-like spread in dementia
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Mar 2018
– Feb 2021
Interactions of Perirhinal Tau Pathology and Aging in Cognitive Dysfunction
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Feb 2018
ACTIVE
Towards Understanding the Biological Role of Newly Discovered Alzheimers Disease Susceptibility Genes Affecting Immune Function
Role: Principal Investigator
Funding: FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER
Sep 2017
– May 2018
APOE as a modifier of prion-like spread in dementia
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Sep 2017
– Nov 2020
Immune modulation and CNS pathology following exogenous a-synuclein challenge
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Aug 2017
– Mar 2021
Pathological spread and outcomes of alpha-synuclein mutants
Role: Co-Investigator
Funding: NATL INST OF HLTH NINDS
Mar 2017
ACTIVE
Towards understanding the role of immune regulation of Apolipoprotein E function in Alzheimers disease proteostasis
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Feb 2017
– Sep 2019
Understanding the molecular mechanisms of seeding and transmission of wild type and mutant tau
Role: Co-Investigator
Funding: FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER
Nov 2016
– Nov 2020
Comparative prionoid and strain properties of tau and synuclein
Role: Principal Investigator
Funding: ALZHEIMERS ASSO
Apr 2016
– May 2017
TOWARDS DETERMINING HOMOTYPIC AND HETEROTYPIC TAUINTERACTIONS IN TAUOPATHY
Role: Principal Investigator
Funding: UF ALZHEIMER'S DISEASE RESEARCH CENTER
Aug 2015
– May 2021
University of Florida – Mt. Sinai Medical Center AD Research Center
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Aug 2015
– Jul 2018
Somatic inactivation of the SNCA locus: a new approach to the understanding and treatment of Parkinson's Disease
Role: Project Manager
Funding: NATL INST OF HLTH NINDS
Aug 2015
– Jan 2017
Chemokine based immunobiotherapeutics in ALS
Role: Principal Investigator
Funding: AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Jul 2013
– Jun 2016
Innate Immune System and tauopathy
Role: Principal Investigator
Funding: BRIGHTFOCUS FOU
Patents
Issued
July 2018
Compounds for Treating Neurodegenerative Proteinopathies
#10,030,067
Published
June 2018
Compounds For Treating Neurodegenerative Proteinopathies (DIV)
#US18/0355018
Education
Postdoctoral Fellow
2005-2010
·
Mayo Clinic
Postdoctoral fellow
2003-2005
·
University of Washington
PhD
1996-2003
·
Jawaharlal Nehru University, New Delhi
MSc
1994-1996
·
University of Calcutta, Calcutta
Teaching Profile
Courses Taught
2019-2021
GMS6757 Introduction to Alzheimer’s Disease and Related Dementias: Clinical and Mechanistic Principles
2017,2019-2020
GMS6750 Molecular Pathobiology of Neural Disease
2017,2019
GMS7794 Neuroscience Seminar
2018
GMS7980 Research for Doctoral Dissertation
2018
GMS7979 Advanced Research
2018
GMS6022 Prin Neuroscience 2
2013,2015-2021,2021
GMS6029 Brain Journal Club
Contact Details
Phones:
- Business:
- (352) 273-7271
Emails:
- Business:
- pchakrabarty@ufl.edu